Skip to main content
Caplight Logo









Invea Therapeutics

Invea Therapeutics

Private
Guilford, ConnecticutHealthcare & Life Scienceshttps://inveatx.com/

Last Round

IPO

Mar 6, 2026

Est. Valuation

$127.5M

Total Funding Raised

$14.76M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Invea Therapeutics is a biotechnology company developing oral small molecule therapeutics for immune-mediated inflammatory diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Medical AI, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

biotechnologydrug discoveryAI drug discoverysmall-molecule therapyimmune-mediated inflammatory diseasesIMIDchymase inhibitorAI-driven biotechclinical-stage biotechinflammasome inhibitorin silico drug discoverymast cell inflammationtherapeutic out-licensingpharma R&DAI-native biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Invea Therapeutics Comparables

Compare Invea Therapeutics with similar companies based on industry and business-model similarity.

Invea Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Evommune
84%
Septerna
79%
Incyte Corporation
75%

Invea Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
IPOMar 6, 2026
Convertible DebtMar 31, 2025
SAFEMar 22, 2023
Series A ExtensionFeb 22, 2023
Series AApr 22, 2022
Debt
Nov 24, 2021

Key People

Founding team and executive leadership

Aman Kant

Co-founder And Chief Operating Officer

Founding Team

Krishnan Nandabalan

Founder, Chairman, President, CEO

Founding Team

Michael Aiello

Chief Financial Officer

Executive Team

Invea Therapeutics Investors

Notable investors and investment history

Invea Therapeutics investors
InvestorRounds
Connecticut InnovationsSeries A, Series A Extension
ThinkEquityIPO

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 19, 2026

    Monthly visitors grew 1200% MoM, from 1.2K to 16K.

  • Mar 6, 2026

    Raised $35M at a $127.5M valuation.

Invea Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Invea Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Invea Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersGuilford, Connecticut
Employee Range7
Year Founded2021
Last FundingMar 6, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?